A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2018
Price : $35 *
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Cardiovascular disorders; Embolism and thrombosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 12 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 01 Sep 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.